Vol. 21/No. 22 | OncologyLive

Infrastructure of Oncology Care Model Helps Practice Through COVID-19

November 27, 2020

Nothing about taking care of patients with cancer during the coronavirus disease 2019 pandemic has been easy, but those practices that had already embraced transformation under the Oncology Care Model are finding that its monthly payments and other features offer stability during an unprecedented health emergency.

New Strategies Enhance Care in mUC

November 25, 2020

Partner Perspectives

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24, 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial

November 23, 2020

Clinical Trial Reports

November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

Real-World Impact of Low-Grade AEs Needs a Closer Look

November 18, 2020

Although PARP inhibitors are generally reasonably well tolerated, certainly compared with platinum and other routinely employed cytotoxic antineoplastic drugs, the majority of patients receiving PARP inhibitors in multiple reported clinical trials reported low-grade nausea and fatigue.